Apriori LLC

BluPax Pharma is an independently owned wholesaler and distributor of prescription pharmaceuticals, dedicated to providing exceptional value, quality, and reliability within the healthcare supply chain. The company serves long-term care facilities, independent retail and specialty pharmacies, hospitals, and chains, leveraging partnerships with over 120 direct manufacturers to maintain a 99.5% fill rate. With a robust catalog of more than 4,000 SKUs across all dosage forms and therapeutic categories, BluPax Pharma emphasizes savings and transparency through competitive pricing and straightforward ordering processes. Its nationwide distribution offers free next-day delivery with minimal order requirements, allowing customers to focus on patient care while BluPax handles the logistics. Generated from the website

Agno Pharma is a global pharmaceutical contract research and manufacturing organization (CRO CMO) that specializes in the research, development, manufacturing, sourcing, marketing, and distribution of chemically and biologically derived pharmaceutical intermediates. With expertise in chemical process manufacturing, high potency APIs, analytical development, cGMP regulatory compliance, and sourcing logistics, Agno Pharma offers a wide range of services including custom synthesis, chemical process development, API section of IND, medicinal chemistry, FTE analytical development, validation, ICH stability storage testing, and sourcing logistics testing.Generated from the website

Enzon Pharmaceuticals is a biopharmaceutical company dedicated to the development and commercialization of therapeutics to treat patients with cancer and other life-threatening diseases. The company s specialized sales force markets Abelcet, Oncaspar, Adagen and Depocyt in North America. In addition, it also receives royalties on sales of Peg-Intron, which is marketed by Schering-Plough Corporation, and Macugen, which is marketed by OSI Pharmaceuticals and Pfizer. The company s product-driven strategy includes a drug development program that leverages its proprietary technologies that includes a next-generation PEGylation platform that utilizes linkers designed to release compounds at a controlled rate. Internal research and development efforts are complemented with strategic initiatives, such as partnerships designed to broaden its revenue base or provide access to promising new technologies or product development opportunities. Enzon Pharmaceuticals is headquartered in Bridgewater, N.J.